Daniel De Carvalho/LinkedIn
Feb 27, 2025, 16:55
Daniel De Carvalho: Chronic viral mimicry after p53 loss enables immune evasion in early ovarian cancer
Daniel De Carvalho, Co-Founder and Chief Scientific Officer of Adela, reshared a post by Research at UHN on LinkedIn:
“Great write-up by University Health Network on our recent publication.
Our study suggests that chronic viral mimicry exposure following p53 loss in early ovarian cancer transformation helps cancer cells evade immune detection.
Key findings:
- Repetitive DNA elements trigger a chronic immune response in early cancer.
- Over time, cancer cells adapt, reducing immune activation and resisting therapy.
- Blocking this process may offer new interception strategies.
Read more here.”
Quoting Research at UHN‘s post:
“Scientists at UHN’s Princess Margaret Cancer Centre have uncovered how cancer adapts to evade immune defenses after losing p53, a key protein implicated in cancer formation.
This process, termed “viral mimicry conditioning” may offer a new target for early cancer interception and treatment.
Read more.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 27, 2025, 13:26
Feb 27, 2025, 13:24
Feb 27, 2025, 13:21
Feb 27, 2025, 13:13